Close Menu

NEW YORK (360Dx) – Vermillion reported after the close of the market on Thursday that its fourth quarter revenues were up 16 percent year over year.

For the three months ended Dec. 31, 2018, the company reported total revenues of $922,000, up from $798,000 in Q4 2017.

Vermillion posted $793,000 in product revenues from sales of its OVA1 ovarian cancer test, up 21 percent from $658,000 in the prior-year quarter. Service revenues from its Aspira IVD business was down 8 percent to $129,000 from $140,000 in Q4 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.